MedKoo product information:

 Tacrolimus

Tacrolimus is a macrolide isolated from the fungus Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

History

Tacrolimus was discovered in 1984 by a Japanese team headed by T. Goto, T. Kino and H. Hatanaka; it was among the first macrolide immunosuppressants discovered, preceded by the discovery of rapamycin (sirolimus) on Rapa Nui (Easter Island) in 1975. Like cyclosporin, it was found in a soil fungus, although it is produced by a type of bacterium, Streptomyces tsukubaensis. The name tacrolimus is derived from 'Tsukuba macrolide immunosuppressant'. Tacrolimus was first approved by the Food and Drug Administration (FDA) in 1994 for use in liver transplantation; this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, bone marrow, and limb transplants. (The information was directly from http://en.wikipedia.org/wiki/Tacrolimus).

DRUG DESCRIPTION

Prograf is available for oral administration as capsules (tacrolimus capsules) containing the equivalent of 0.5 mg, 1 mg or 5 mg of anhydrous tacrolimus. Inactive ingredients include lactose, hydroxypropyl methylcellulose, croscarmellose sodium, and magnesium stearate. The 0.5 mg capsule shell contains gelatin, titanium dioxide and ferric oxide, the 1 mg capsule shell contains gelatin and titanium dioxide, and the 5 mg capsule shell contains gelatin, titanium dioxide and ferric oxide. Prograf is also available as a sterile solution (tacrolimus injection) containing the equivalent of 5 mg anhydrous tacrolimus in 1 mL for administration by intravenous infusion only. Each mL contains polyoxyl 60 hydrogenated castor oil (HCO-60), 200 mg, and dehydrated alcohol, USP, 80.0% v/v. Prograf injection must be diluted with 0.9% Sodium Chloride Injection or 5% Dextrose Injection before use. Tacrolimus, previously known as FK506, is the active ingredient in Prograf. Tacrolimus is a macrolide immunosuppressant produced by Streptomyces tsukubaensis. Tacrolimus has an empirical formula of C44H69NO12•H2O and a formula weight of 822.03. Tacrolimus appears as white crystals or crystalline powder. It is practically insoluble in water, freely soluble in ethanol, and very soluble in methanol and chloroform.

Mechanism of Action

Tacrolimus prolongs the survival of the host and transplanted graft in animal transplant models of liver, kidney, heart, bone marrow, small bowel and pancreas, lung and trachea, skin, cornea, and limb. In animals, tacrolimus has been demonstrated to suppress some humoral immunity and, to a greater extent, cell-mediated reactions such as allograft rejection, delayed type hypersensitivity, collagen-induced arthritis, experimental allergic encephalomyelitis, and graft versus host disease. Tacrolimus inhibits T-lymphocyte activation, although the exact mechanism of action is not known. Experimental evidence suggests that tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin inhibited. This effect may prevent the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines (such as interleukin-2, gamma interferon). The net result is the inhibition of T-lymphocyte activation (i.e., immunosuppression).

 1: Choi BH, Feng L, Yoon HS. FKBP38 protects Bcl-2 from caspase-dependent degradation. J Biol Chem. 2010 Mar 26;285(13):9770-9. Epub 2010 Feb 5. PubMed PMID: 20139069; PubMed Central PMCID: PMC2843226.

2: Marinelli F. Chapter 2. From microbial products to novel drugs that target a multitude of disease indications. Methods Enzymol. 2009;458:29-58. PubMed PMID: 19374978.

3: Neklesa TK, Davis RW. Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15166-71. Epub 2008 Sep 23. PubMed PMID: 18812505; PubMed Central PMCID: PMC2567509.

4: Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Des. 2008;14(17):1723-42. Review. PubMed PMID: 18673195.

5: Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res. 2008 Apr 15;68(8):2934-43. PubMed PMID: 18413763.

6: Veverka V, Crabbe T, Bird I, Lennie G, Muskett FW, Taylor RJ, Carr MD. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene. 2008 Jan 24;27(5):585-95. Epub 2007 Aug 6. PubMed PMID: 17684489.

7: De A, Loening AM, Gambhir SS. An improved bioluminescence resonance energy transfer strategy for imaging intracellular events in single cells and living subjects. Cancer Res. 2007 Aug 1;67(15):7175-83. PubMed PMID: 17671185.

8: Hara Y, Nakajima M, Miyamoto K, Yokoi T. Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. Drug Metab Pharmacokinet. 2007 Apr;22(2):103-12. PubMed PMID: 17495417.

9: Yang XX, Hu ZP, Duan W, Zhu YZ, Zhou SF. Drug-herb interactions: eliminating toxicity with hard drug design. Curr Pharm Des. 2006;12(35):4649-64. Review. PubMed PMID: 17168768.

10: Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol. 2005 Oct;18(5):574-80. Review. PubMed PMID: 16155443.

11: Rivera A, Maxwell SA. The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway. J Biol Chem. 2005 Aug 12;280(32):29346-54. Epub 2005 May 23. PubMed PMID: 15914462.

12: Ritacco FV, Graziani EI, Summers MY, Zabriskie TM, Yu K, Bernan VS, Carter GT, Greenstein M. Production of novel rapamycin analogs by precursor-directed biosynthesis. Appl Environ Microbiol. 2005 Apr;71(4):1971-6. PubMed PMID: 15812028; PubMed Central PMCID: PMC1082568.

13: Banaszynski LA, Liu CW, Wandless TJ. Characterization of the FKBP.rapamycin.FRB ternary complex. J Am Chem Soc. 2005 Apr 6;127(13):4715-21. Erratum in: J Am Chem Soc. 2006 Dec 13;128(49):15928. PubMed PMID: 15796538.

14: Joerger M, Schellens JH, Beijnen JH. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. Methods Find Exp Clin Pharmacol. 2004 Sep;26(7):531-45. Review. PubMed PMID: 15538543.

15: Weisman R, Roitburg I, Nahari T, Kupiec M. Regulation of leucine uptake by tor1+ in Schizosaccharomyces pombe is sensitive to rapamycin. Genetics. 2005 Feb;169(2):539-50. Epub 2004 Sep 30. PubMed PMID: 15466417; PubMed Central PMCID: PMC1449110.

16: Rossi A, Pica-Mattoccia L, Cioli D, Klinkert MQ. Rapamycin insensitivity in Schistosoma mansoni is not due to FKBP12 functionality. Mol Biochem Parasitol. 2002 Nov-Dec;125(1-2):1-9. PubMed PMID: 12467969.

17: Crespo JL, Hall MN. Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol Mol Biol Rev. 2002 Dec;66(4):579-91, table of contents. Review. PubMed PMID: 12456783; PubMed Central PMCID: PMC134654.

18: Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol. 2002 Dec;22(23):8184-98. PubMed PMID: 12417722; PubMed Central PMCID: PMC134072.

19: Chiurchiu C, Ruggenenti P, Remuzzi G. Thrombotic microangiopathy in renal transplantation. Ann Transplant. 2002;7(1):28-33. Review. PubMed PMID: 12221901.

20: Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res. 2002;160:251-8. PubMed PMID: 12079221.

21: Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat. 2001 Dec;4(6):378-91. Review. PubMed PMID: 12030785.

22: Gornet JM, Lokiec F, Duclos-Vallee JC, Azoulay D, Goldwasser F. Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma. Anticancer Res. 2001 Nov-Dec;21(6A):4203-6. PubMed PMID: 11911319.

23: Zhu W, Zhang JS, Young CY. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis. 2001 Sep;22(9):1399-403. PubMed PMID: 11532861.

24: Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood. 2001 Jun 1;97(11):3505-12. PubMed PMID: 11369644.

25: Tanaka K, Hirai M, Tanigawara Y, Yasuhara M, Hori R, Ueda K, Inui K. Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. Pharm Res. 1996 Jul;13(7):1073-7. PubMed PMID: 8842048.

26: Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 Mar 25;268(9):6077-80. PubMed PMID: 7681059.